Bern, Switzerland-based Ikerian and its subsidiary, RetinAI, a Boston, MA-based developer of software solutions for medical image and data management, and artificial intelligence (AI) in healthcare, raised USD 8M in the first close of its Series B funding.
The round was led by Sanoptis, with participation from existing investors the THINC Ventures arm of Topcon Healthcare, Zürcher Kantonalbank, and Verve Ventures.
The company intends to use the funds for continued development and commercial roll out of RetinAI Discovery®, its AI models and Discovery CONNECT™ to increase automation and data connectivity into ophthalmology and optometry care, continue to build a database of real-world evidence (RWE), and integrate AI-driven patient pre-screening technology to accelerate clinical studies.
Led by Dr. Carlos Ciller, Chairman and CEO of Ikerian, and CEO of RetinAI, Ikerian (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc., develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision, across ophthalmology, neurodegenerative disorders, vascular conditions, and rare diseases. Focused on the ophthalmology and optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare.
RetinAI has established collaborations and partnerships with ophthalmology and pharmaceutical companies including RetinAI Consultants of America (RCA), Boehringer Ingelheim, J&J and Novartis.
FinSMEs
16/10/2024